LUYE PHARMA (02186.HK): Ruoxinlin Wins China Nod for Anxiety Disorder

On 19 November 2026, LUYE PHARMA (02186.HK) said NMPA approved Ruoxinlin for generalized anxiety disorder, its second indication in China after depression.

NewTimeSpace News: On 19 November 2026, Luye Pharma Group Ltd. (stock code: 02186.HK) announced that Ruoxinlin® (toludesvenlafaxine hydrochloride sustained-release tablets), a Class 1 innovative drug independently developed by the Group, has been approved by China's National Medical Products Administration for the treatment of generalized anxiety disorder (GAD). The company said the product is the first innovative chemical drug for anxiety developed in China with proprietary intellectual property rights, marking a major breakthrough for domestically developed innovative drugs in the therapeutic area.

Ruoxinlin® was first approved in China in November 2022 for major depressive disorder, and GAD is its second approved indication in the country. It is China's first and currently only serotonin, norepinephrine and dopamine triple reuptake inhibitor (SNDRI).

The approval is based on an eight-week, multicentre, randomised, double-blind, placebo-controlled Phase III study using the change from baseline in the Hamilton Anxiety Rating Scale total score as the primary endpoint. Ruoxinlin® began to take effect as early as week 1; after eight weeks the response rate exceeded 80% and the remission rate was about 50%, with significant improvements in psychic anxiety, somatic anxiety and core symptoms. The product showed a favourable safety and tolerability profile, with no significant impact on body weight or glucose and lipid metabolism and low rates of somnolence, insomnia, fatigue and sexual dysfunction.

Citing IQVIA, the company said China's antidepressant and anti-anxiety drug markets together totalled RMB9.78 billion in 2025 and RMB5.08 billion in the first half of 2026. Ruoxinlin® is recommended as a first-line treatment for depression in the Chinese Guidelines for the Diagnosis and Treatment of Depressive Disorders (2025 Edition) and the Chinese Guidelines for the Prevention and Treatment of Depression in the Community.

×
Share to WeChat

Open WeChat, use the "Scan", and share to my Moments.